Robert L Hollis

15PUBLICATIONS
67CO-AUTHORS
Predictive and prognostic markersPhylogeny and comparative analysisCancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Dec 11, 2025
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Robert L Hollis, Austin Miller, Heather A Lankes

|Jul 24, 2025
Oxford Classic-Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions.

Lena Rai, Antonella Ravaggi, Eliana Bignotti

|Jul 02, 2025
Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer.

Ailith Ewing, Alison Meynert, Ryan Silk

|Jun 21, 2024
The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype specific.

Joanna M Porter, Iona McFarlane, Clare Bartos

|Dec 14, 2023
Compartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.

C Simon Herrington, Ailsa J Oswald, Lorna J Stillie

|Jun 17, 2022
Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma.

Robert L Hollis, Ian Croy, Michael Churchman

Pageof 3

Frequent Collaborators

10 joint publications

C Simon Herrington

7 joint publications

Charlie Gourley

5 joint publications

Michael Churchman

4 joint publications

Colin A Semple